{"id":1464,"date":"2014-08-12T00:00:00","date_gmt":"2014-08-12T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/"},"modified":"2023-06-14T19:57:04","modified_gmt":"2023-06-14T23:57:04","slug":"real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/","title":{"rendered":"Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis"},"content":{"rendered":"

Background<\/strong> — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to CHOP alone as first-line treatment of DLBCL, but it remains unclear what its real-world costs and cost-effectiveness are in routine clinical practice.<\/p>\n

Methods<\/strong> — The authors performed a population-based retrospective cohort study from 1997 to 2007, using linked administrative databases in Ontario, Canada, to evaluate the costs and cost-effectiveness of RCHOP compared to CHOP alone. A historical control cohort (n = 1,099) with DLBCL who received CHOP before rituximab approval was hard-matched on age and treatment intensity and then propensity-score matched on sex, comorbidity, and histology to 1,099 RCHOP patients. All costs and outcomes were adjusted for censoring using the inverse probability weighting method. The main outcome measure was incremental cost per life-year gained (LYG).<\/p>\n

Results<\/strong> — Rituximab was associated with a life expectancy increase of 3.2 months over 5 years at an additional cost of $16,298, corresponding to an incremental cost-effectiveness ratio of $61,984 (95% CI $34,087-$135,890) per LYG. The probability of being cost-effective was 90% if the willingness-to-pay threshold was $100,000\/LYG. The cost-effectiveness ratio was most favourable for patients less than 60 years old ($31,800\/LYG) but increased to $80,600\/LYG for patients 60-79 years old and $110,100\/LYG for patients >=80 years old. We found that post-market survival benefits of rituximab are similar to or lower than those reported in clinical trials, while the costs, incremental costs and cost-effectiveness ratios are higher than in published economic models and differ by age.<\/p>\n

Conclusions<\/strong> — Results showed that the addition of rituximab to standard CHOP chemotherapy was associated with improvement in survival but at a higher cost, and was potentially cost-effective by standard thresholds for patients <60 years old. However, cost-effectiveness decreased significantly with age, suggesting that rituximab may be not as economically attractive in the very elderly on average. This has important clinical implications regarding age-related use and funding decisions on this drug.<\/p>\n","protected":false},"excerpt":{"rendered":"

Background — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to CHOP alone as first-line treatment of DLBCL, but it remains unclear what its real-world costs and cost-effectiveness are in […]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[38,61],"migration-helper-qa-sample-set":[],"class_list":["post-1464","journal_article","type-journal_article","status-publish","hentry","topic-cancer-and-cancer-screening","topic-health-economics"],"acf":{"citation":"Khor S, Beca J, Krahn M, Hodgson D, Lee L, Crump M, Bremner KE, Luo J, Mamdani M, Bell CM, Sawka C, Gavura S, Sullivan T, Trudeau M, Peacock S, Hoch JS. BMC Cancer<\/em>. 2014; 14:586. Epub 2014 Aug 12.","source_url":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-586","ices_scientist":[1261,1325,1172,17132],"site":[6735,6733],"research_program":[6746,6741],"news_release":[],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"049A0DF2-B512-4B7C-BE7B-B0A4BD4433E1","sitecore_item_name":"Real-world-costs-and-cost-effectiveness-of-Rituximab-for-diffuse-large-B-Cell-lymphoma-patients","sitecore_field_values":"{\n \"Title\": \"Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis\",\n \"Short title\": \"Real world costs and cost-effectiveness\",\n \"Citation\": \"

Khor S, Beca J, Krahn M, Hodgson D, Lee L, Crump M, Bremner KE, Luo J, Mamdani M, Bell CM, Sawka C, Gavura S, Sullivan T, Trudeau M, Peacock S, Hoch JS. BMC Cancer<\/em>. 2014; 14:586. Epub 2014 Aug 12.<\/p>\",\n \"Abstract\": \"

Background<\/strong> — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to CHOP alone as first-line treatment of DLBCL, but it remains unclear what its real-world costs and cost-effectiveness are in routine clinical practice.<\/p>n

Methods<\/strong> — The authors performed a population-based retrospective cohort study from 1997 to 2007, using linked administrative databases in Ontario, Canada, to evaluate the costs and cost-effectiveness of RCHOP compared to CHOP alone. A historical control cohort (n = 1,099) with DLBCL who received CHOP before rituximab approval was hard-matched on age and treatment intensity and then propensity-score matched on sex, comorbidity, and histology to 1,099 RCHOP patients. All costs and outcomes were adjusted for censoring using the inverse probability weighting method. The main outcome measure was incremental cost per life-year gained (LYG).<\/p>n

Results<\/strong> — Rituximab was associated with a life expectancy increase of 3.2 months over 5 years at an additional cost of $16,298, corresponding to an incremental cost-effectiveness ratio of $61,984 (95% CI $34,087-$135,890) per LYG. The probability of being cost-effective was 90% if the willingness-to-pay threshold was $100,000\/LYG. The cost-effectiveness ratio was most favourable for patients less than 60 years old ($31,800\/LYG) but increased to $80,600\/LYG for patients 60-79 years old and $110,100\/LYG for patients >=80 years old. We found that post-market survival benefits of rituximab are similar to or lower than those reported in clinical trials, while the costs, incremental costs and cost-effectiveness ratios are higher than in published economic models and differ by age.<\/p>n

Conclusions<\/strong> — Results showed that the addition of rituximab to standard CHOP chemotherapy was associated with improvement in survival but at a higher cost, and was potentially cost-effective by standard thresholds for patients <60 years old. However, cost-effectiveness decreased significantly with age, suggesting that rituximab may be not as economically attractive in the very elderly on average. This has important clinical implications regarding age-related use and funding decisions on this drug.<\/p>n

View full text<\/a><\/p>\",\n \"Keywords\": \"{4F321D0E-F7F1-4C8D-B2FE-922AD8DE3C78}|{7BE0FF11-FF68-43B8-9042-F6AC230D57DB}|{0E662B44-FE02-4F02-9E07-94810A5E1754}\",\n \"Research Programs\": \"{CFE36C89-C969-4C23-B5E4-1BA9E5BDC273}|{85DE96A6-4C96-40C7-8E6D-7597A0EB5F80}\",\n \"ICES Locations\": \"{FBE2D1B1-C0BA-423F-8D16-39466B6C1424}|{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\n \"ICES Scientists\": \"{9EB22F72-67F1-409E-AB1B-D1C045367A84}|{0FDA1DFE-97C3-41FE-AD90-6966265DC178}|{F2F916BC-2EE9-4C65-BCAB-086ED6BB971A}|{9F60496B-63FD-4BE5-A7EF-C4969D7AACB3}\",\n \"Posted Date\": \"20140812T000000\",\n \"Show on Publications Landing Page\": \"1\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2014\/January\/Real-world-costs-and-cost-effectiveness-of-Rituximab-for-diffuse-large-B-Cell-lymphoma-patients"},"yoast_head":"\nICES | Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis<\/title>\n<meta name=\"description\" content=\"Background — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide,\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis\" \/>\n<meta property=\"og:description\" content=\"Background — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T23:57:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\\\/\",\"name\":\"ICES | Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2014-08-12T04:00:00+00:00\",\"dateModified\":\"2023-06-14T23:57:04+00:00\",\"description\":\"Background — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide,\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis","description":"Background — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide,","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis","og_description":"Background — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide,","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T23:57:04+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/","name":"ICES | Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2014-08-12T04:00:00+00:00","dateModified":"2023-06-14T23:57:04+00:00","description":"Background — Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide,","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/real-world-costs-and-cost-effectiveness-of-rituximab-for-diffuse-large-b-cell-lymphoma-patients-a-population-based-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/1464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6741"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6735"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/17132"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1325"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1261"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=1464"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=1464"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=1464"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=1464"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=1464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}